================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
----------------------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): October 17, 2006
Critical Therapeutics, Inc.
(Exact Name of Registrant as Specified in Charter)
Delaware 000-50767 04-3523569
(State or Other Jurisdiction (Commission (IRS Employer
of Incorporation) File Number) Identification No.)
60 Westview Street, Lexington, Massachusetts 02421
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (781) 402-5700
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
|_| Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
================================================================================
Item 8.01. Other Events.
On October 17, 2006, Critical Therapeutics, Inc. announced that the U.S. Food
and Drug Administration has accepted for filing its New Drug Application for the
twice-daily, controlled-release formulation of zileuton, an investigational drug
developed for the prevention and chronic treatment of asthma in adults and
children 12 years of age and older. A copy of the press release is filed as
Exhibit 99.1 attached hereto and incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
The Exhibit Index attached to this Report is incorporated herein by reference.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: October 17, 2006 CRITICAL THERAPEUTICS, INC.
By: /s/ Frank E. Thomas
--------------------------------------
Frank E. Thomas
President
EXHIBIT INDEX
Exhibit No. Description
----------- -----------
99.1 Press Release dated October 17, 2006